Project Grant RF1AG074256
Award Date
8/1/22
Completion Date
7/31/25
Dollars Obligated
$4.4M
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This Project Grant award for $506,451 from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) aims to develop an effective targeted delivery system for small interfering RNA (siRNA) therapeutics to mitigate neuroinflammatory diseases, including Alzheimer's disease. The project leverages the awardee's 3P Biotechnologies, Inc.'s expertise in exosome engineering, drug delivery, and siRNA therapeutics. The key products or services to be delivered under this award...
This three-year $3.16 million project grant from the National Institutes of Health's National Institute on Aging will fund research into the role of ceramide in extracellular vesicle-mediated neurodegenerative disease processes like Alzheimer's. Specifically, the University of Kentucky Research Foundation will investigate how ceramide contributes to the formation and toxicity of astrocyte-derived extracellular vesicles known as "astrosomes" that bind to amyloid-beta, a pathological...
This is a Project Grant award from the National Institute on Aging (NIA), part of the Department of Health and Human Services, under the Aging Research Federal Grant Program (CFDA 93.866). The $787,103 award to Vanderbilt University aims to develop a novel siRNA-lipid conjugate ("siRNA-EG18") to silence target genes in brain myeloid cells, including microglia and macrophages, as a potential treatment approach for Alzheimer's disease. The award will fund comprehensive gene and protein...
The National Institute on Aging awarded a $1,931,965 Project Grant (CFDA 93.866 - Aging Research) to the Regenerative Research Foundation, a non-profit organization in Albany, New York. The purpose of this federal grant is to develop and validate a novel human induced pluripotent stem cell (iPSC) model that incorporates cerebral cortical neurons, glia, vascular endothelial cells, and microglia to study cerebrovascular interactions in Alzheimer's disease-related dementias (ADRD). The R61 phase of...
This federal Project Grant award, funded by the National Institute on Aging (CFDA 93.866 - Aging Research), provides $810,596 to New York University School of Medicine to develop an "off-the-shelf" chimeric antigen receptor (CAR) therapy for Alzheimer's disease. The key products/services to be delivered include: Optimizing a protocol to efficiently transdifferentiate human induced pluripotent stem cells (hiPSCs) into self-sustaining, immunomodulatory macrophage/microglia (iMI) cells....
This federal Project Grant award, with an ID of R21AG089268, was provided by the National Institute on Aging under the Aging Research program (CFDA 93.866). The $664,000 award, effective from August 15, 2024 to May 31, 2026, will fund research at the University of Southern California to investigate the role of meningeal lymphatic dysfunction in Alzheimer's disease pathogenesis. The key aims of the project are to determine whether craniosynostosis, a craniofacial disorder, is a risk factor for...
This $374,000 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) is funding the development and evaluation of a novel hematopoietic stem cell-based chimeric antigen receptor (CAR) macrophage therapy for Alzheimer's disease (AD). The key objectives are to: 1) Optimize an AB-targeting CAR macrophage for in vitro efficacy against AB aggregates and inflammation reduction, and 2) Investigate the safety and central nervous system trafficking of the CAR...
The National Institute on Aging (NIA) awarded a $295,000 Project Grant under the Aging Research program (CFDA 93.866) to Florida International University (FIU). The 2-year award, effective from September 15, 2024 to August 31, 2026, aims to develop a novel biotherapeutic nanogel system to target key biomarkers of Alzheimer's disease (AD). The proposed nanogels are designed to enhance blood-brain barrier penetration, inhibit amyloid-beta aggregation, and mitigate oxidative stress and...
This National Institute on Aging (NIA) Project Grant award for $734,778 under the Aging Research program (CFDA 93.866) is supporting research to develop a novel, scalable allogeneic cell therapy platform capable of addressing both tau-mediated pathology and associated inflammation in Alzheimer's disease and related dementias. The project aims to engineer chimeric antigen receptor (CAR) macrophages derived from human induced pluripotent stem cells (iPSCs) to target pathogenic tau protein and...
This $759,095 Aging Research project grant (CFDA 93.866) awarded by the National Institute on Aging will develop and deploy MR image-guided focused ultrasound (FUS) technology to deliver SHIP-1 neutralizing therapies across the blood-brain barrier to microglia, with the goal of improving amyloid-beta phagocytosis and restoring neuronal health in Alzheimer's disease mouse models. The University of Virginia is the prime awardee for this 5-year project, which aims to be the first implementation...